Prosecution Insights
Last updated: November 04, 2026
Application No. 17/777,100

METHOD FOR DETECTING LUNG CANCER

Final Rejection §101§112
Filed
May 16, 2022
Priority
Nov 15, 2019 — nonprovisional of PCTGB2019053245
Examiner
VASSELL, MEREDITH ABBOTT
Art Unit
1687
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sierra Medical Ltd.
OA Round
2 (Final)
30%
Grant Probability
At Risk
3-4
OA Rounds
3m
Est. Remaining
76%
With Interview

Examiner Intelligence

Grants only 30% of cases
30%
Career Allowance Rate
20 granted / 67 resolved
-30.1% vs TC avg
Strong +46% interview lift
Without
With
+45.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 8m
Avg Prosecution
29 currently pending
Career history
112
Total Applications
across all art units

Statute-Specific Performance

§101
32.3%
-7.7% vs TC avg
§103
30.3%
-9.7% vs TC avg
§102
3.9%
-36.1% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 67 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 1, 3-4, 6-14, 16-18, 22, 24, 25, 30, and 34-38 are pending and under examination.. Claims 1, 3-4, 6-14, 16-18, 22, 24, 25, 30, and 34-38 are rejected. Claims 2, 5, 15, 19-21, 23, 26-29, 31-33 are canceled. Claims 1, 30, and 34 and independent. Claims 34-38 are new. No claims are allowed or withdrawn. Office Action Overview Rejections applied Abbreviations x 112/b Indefiniteness PHOSITA "a Person Having Ordinary Skill In The Art before the effective filing date of the claimed invention" 112/b "Means for" BRI Broadest Reasonable Interpretation 112/a Enablement, Written description CRM "Computer-Readable Media" and equivalent language 112 Other IDS Information Disclosure Statement 102, 103 JE Judicial Exception x 101 JE(s) 112/a 35 USC 112/a and similarly for 112/b, etc. 101 Other N:N page:line Double Patenting MM/DD/YYYY date format Priority As detailed in the 01/20/2023 filing receipt, this application is a 371 of PCT/GB2019/053245, filed 11/15/2019. At this point in examination, all claims have been interpreted as being accorded this priority date. Overview of Withdrawal/Revision of Objections/Rejections In view of the amendment and remarks received 07/14/2026: • The claim objection is withdrawn. • The previous 112b rejections are withdrawn, and new rejections are applied. • The 101 rejection for matter belonging to no statutory category is withdrawn. Applicant's amending of claims 1, 3-4, 6-14, 16-18, 22, 24, and 25 to recite "non-transitory" is acknowledged. • The 101 rejection for matter reciting judicial exceptions is maintained with revision. • The 102 rejection is withdrawn at least because close art, for example Lewis, (BMC cancer, vol. 10(1):640, pp.1-10 (2010); cited on the 05/24/2022 IDS) as cited in the now withdrawn 102 rejection, as well as Krafft (Journal of biophotonics, vol. 2(1‐2), pages 13-28 (2009); cited on the attached form PTO-892), as well as other art found in the search histories and on the IDSs, while showing use of spectroscopy in diagnosing lung disease, does not teach at least the instant and particularly-recited features for each spectrum is obtained from a different cell from the sample and diagnosing the lung disease by determining the distribution of a plurality features of the plurality of spectra to be asymmetric; and diagnosing the lung disease based on the asymmetric distribution. It is not clear that any combinable art of record would have rendered the claims obvious. In this regard, Applicant's 7/14/2026 remarks at pp. 12-16 support withdrawal of the rejection. Claim Interpretation Claims 1, 3, 7, 8, 11, 18, 30, and 38 recite the terms "feature of interest" and/or "features of interest." The terms "feature of interest" and "features of interest" are interpreted as value and values which might include: "a peak area in a spectroscopic band of interest; a mean value, an ordinary arithmetic mean, a weighted arithmetic mean or a centroid within a spectroscopic band of interest; a value at a wavenumber of interest; and/or a wavenumber at which a spectroscopic maximum or minimum occurs within a spectroscopic band of interest" as disclosed in Specification 3:1-5. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 14, 22, 25, and 34-38 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims depending from rejected claims are rejected similarly, unless otherwise noted, and any amendments in response to the following rejections should be applied throughout the claims, as appropriate. The below-listed recitations of claims 14, 22, 25, 34, and 38 require but lack clear antecedent. If the recitations refer to previously instantiated instances, then it is not clear which instances those are. If the recitations instantiate the claim elements, this is not clear. • the upper respiratory tract (claims 14 and 34) • the region (four times in claim 22; amend each instance to "a region") • the nucleus (claim 25) • the 1200-900 cm-1 region (claims 34 and 38) These rejections might be overcome by for example amending "the" to "a" or by simply deleting "the" from the limitation lacking clear antecedent. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Response to Applicant Arguments - 35 USC § 101 Applicant's 7/14/2026 arguments have been fully considered but they are not yet persuasive. Regarding Step 2B analysis as to conventionality of additional elements Referring to 101 analysis as organized in MPEP 2106, Applicant's remarks are understood to address Step 2B (MPEP 2106.05). Applicant asserts: • "Claim 1 amounts to significantly more than a judicial exception (Step 2B)." (p.9, ¶ 5) • "The features of claim 1 recite obtaining features of interest..., determining a distribution of these features..., and diagnosing lung disease in case this distribution is asymmetric. It is not accepted that these features are 'well-understood, routine, conventional activity'." (p.9, ¶ 7) • ..."the contribution of the inventive concept is the possibility that a lung disease may be diagnosed from a distribution of features from different spectra." (bridging p.9-10) • "In Pahlow, the examples of cancer detection given do not compare data points across multiple spectra and determine their distribution...but the present invention introduces an inventive and unconventional new means of data analysis involving determining a distribution of features between different spectra of different cells"... (p.10, ¶ 3) • "Talari describes the same conventional approaches as Pahlow"...(p.10, ¶ 4) • "In each of these examples, lung cancer is indicated by shifts or differences in absorption in peaks as determined from comparing an individual spectrum with a normal or healthy spectrum. None of these methods contemplates the idea that features of interest from multiple spectra obtained from multiple cells may be compared in order to determine a distribution of these, and determine lung disease from an asymmetric distribution." (p.11, ¶ 5) • ..."example 29, 'Diagnosing and Treating Julitis,' because they recite steps that are not 'routinely or conventionally used' and include 'an unconventional step that is more than a mere instruction to "apply" the correlation and critical thinking step (the exception) using well understood, routine or conventional techniques in the field... the steps of identifying features,...determining a distribution...and diagnosing based on an asymmetric distribution are similarly not 'routinely or conventionally used' and include 'an unconventional step that is more than a mere instruction to "apply" the correlation and critical thinking step (the exception) using well-understood, routine or conventional techniques in the field"... (bridging p.11-12) The 101 arguments are not yet persuasive because at Step 2B of the 101 analysis the additional elements are evaluated, individually and in combination, to determine if they amount to significantly more than the judicial exception or if the additional elements are well-understood, routine, and conventional. (See MPEP § 2106.05.) In the instant invention, the additional elements of data gathering and computer components are conventional as put forth in the 101 rejection below. The entirety of the data analysis, including determining distributions and diagnosis of the disease, comprises the judicial exception (abstract ideas in this case), however, judicial exceptions are not analyzed for conventionality as additional elements are at Step 2B. Therefore, the arguments regarding Pahlow and Talari for not showing the specific points of the analysis for diagnosing and distributions are not persuasive, as Pahlow and Talari have been cited in Step 2B of the 101 analysis below only to show the conventionality of the additional element of data gathering, not of the abstract ideas. Additionally, the arguments concerning claims 3 and 4 of SME Examples 29 (May 2016) are not persuasive, not least because the fact pattern differs between Example 29 (diagnosing Julitis by immunoassay) and the instant application (determining lung disease by cell analysis using spectroscopic feature distributions). In claims 3 and 4 of Example 29, the non-conventional additional elements are respectively the porcine and the mAb-D33 antibodies used in the immunoassays, not abstract ideas or a law of nature. To reiterate, consideration of non-conventionality of judicial exceptions is not included in the 101 analysis. In the instant application, the claims recite additional elements which are conventional at Eligibility Step 2B. Regarding Step 2A, Prong Two, 1st consideration and improvement Instead, it may be useful to attempt to show a practical application at Step 2A Prong Two. The MPEP at 2106.04(d)(I) lists five example considerations for evaluating whether a judicial exception is integrated into a practical application at Step 2A Prong Two. In the case of the instant application, it may be successful to consider arguments pertaining to an improvement over the prior technology in an attempt to overcome the 101. Regarding an improvement to technology, the record, including Applicant's remarks and the Specification, does not yet clearly disclose an explanation of improvement over the previous state of the technology field, and the claims do not yet clearly result in such an improvement. Providing evidence or detailed explanation of the technical improvement may help to overcome a 101 rejection, (see MPEP 2106.04(d) and (d)(1), as well as MPEP 2106.05(a)). The explanation might include: a concise statement of the improvement, including improvement over the previous state of the technology field; identification of the technology field; explanation of how the claims deliver the improvement and that reasonably all embodiments within the claim scope also will result in the asserted improvement, and extension of the explanation to persuasively demonstrate the nexus of integration of the judicial exceptions into a practical application. As further examples, arguments may clearly and adequately explain cause and effect leading to improvement or, for example, when such cause and effect explanation is not possible, then may include evidence (e.g. experimental data) comparing a claimed result to conventional results. Also, arguments and evidence may be extrinsic to the original disclosure, including references available after the priority date, as long as it is clear that an argument applies to all embodiments of a properly supported claim. In the present invention, the 07/14/2026 arguments do not attempt to explain an improvement. Applicant is encouraged to request an interview to discuss 101 and any other issues. 101 rejection: Claims 1, 3-4, 6-14, 16-18, 22, 24, 25, 30, and 34-38 are rejected under 35 U.S.C. 101 because the claimed invention is directed to one or more judicial exceptions without significantly more. MPEP 2106 details the following framework to analyze Subject Matter Eligibility: • Step 1: Are the claims directed to a category of statutory subject matter (a process, machine, manufacture, or composition of matter)? (see MPEP § 2106.03) • Step 2A, Prong One: Do the claims recite a judicially recognized exception, i.e. an abstract idea, a law of nature, or a natural phenomenon? (see MPEP § 2106.04(a), 2106.04(a)(2) and 2106.04(b)) • Step 2A, Prong Two: If the claims recite a judicial exception under Prong One, then is the judicial exception integrated into a practical application? (see MPEP § 2106.04(d)) • Step 2B: If the claims do not integrate the judicial exception, do the claims provide an inventive concept? (see MPEP § 2106.05) Step 1: Claims 1, 3-4, 6-14, 16-18, 22, 24, 25, and 34-37 are directed to a 101 machine or manufacture, here a non-transitory computer readable medium. Claims 30 and 38 are directed to a 101 process, here a method. As such, claims 1, 3-4, 6-14, 16-18, 22, 24, 25, 30, and 34-38 are directed to categories of statutory subject matter. (See MPEP § 2106.03). (Step 1: Yes.) Step 2A, Prong One: The claims recite judicial exceptions of abstract ideas in the form of mental processes and mathematical concepts as follows: • determining a feature of interest from each spectrum (claims 1, 30, 38) • determining a distribution of the features (claims 1 and 30) • diagnosing a lung disease in dependence on the distribution (claims 1 and 30) • diagnosing a lung disease if distribution is asymmetric (claim 1, 30, 38) • determining a ratio of outliers to non-outliers (claim 3) • determining asymmetry based on the ratio (claim 3) and threshold (claim 4) • determining outliers using a one sided (claim 6) or a two sided (claim 12) boundary • determining one-sided boundary (claim 7) • determining an asymmetry measure and asymmetry (claim 8) • diagnosing lung disease if the distribution spread over a threshold (claim 10) • determining ratios and a spread above the distribution (claim 11) • determining standard deviation (claim 13) • determining a peak area within 1200-900 (claim 34 and 38) • determining a measure of distribution of the set of values as a measure of asymmetry (claim 34 and 38) • diagnosing lung cancer if the measure of distribution indicates an asymmetric distribution in the set of values (claim 34) Claims which further limit one or more of the abstract ideas of one or more base claims above include: Claim 9, which further limits the asymmetry measure of claim 8; claim 18 further limits the feature of claim 1; claim 22 further limits the band of interest of claim 18; claim 24 further limits the lung disease of claim 1; claim 35 further limits the measure of distribution of claim 34; claim 36 further limits the determining an asymmetric distribution of claim 34; claim 37 further limits the determining of the one-sided boundary of claim 34.; claim 38 further limits the determining a feature and determining a distribution of features of claim 30. Step 2A Prong One summary: When considering the BRI of claims 1 and 30, the steps of determining a feature of interest, determining a distribution of the feature, and diagnosing lung disease based on the distribution recite abstract ideas of mental processes because the data analysis steps, as recited, could be performed in the human mind, or with pencil and paper. Additionally, the limitations for: determining a distribution; determining a ratio of outliers; determining an asymmetry measure, a skew, a Pearson's skew, and/or a kurtosis; determining a standard deviation; etc., recite inherent mathematical concepts such as those disclosed in Specification throughout pp. 8-10. Therefore, the claims recite elements that constitute a judicial exception in the form of abstract ideas. (Step 2A, Prong One: Yes.) Step 2A, Prong Two: In Step 2A, Prong One above, claim steps and/or elements were identified as part of one or more judicial exceptions (JEs). Here at Step 2A, Prong Two, any remaining steps and/or elements not identified as JEs are therefore in addition to the identified JE(s), and are considered additional elements. Because the claims have been interpreted as being directed to judicial exceptions, abstract ideas in this instance, then Step 2A, Prong Two provides that the claims be examined further to determine whether the judicial exception is integrated into a practical application [see MPEP § 2106.04(d)]. A claim can be said to integrate a judicial exception into a practical application when it applies, relies on, or uses the judicial exception in a manner that imposes a meaningful limit on the judicial exception. MPEP § 2106.04(d)(I) lists the following example considerations for evaluating whether a judicial exception is integrated into a practical application: (1) An improvement in the functioning of a computer or an improvement to other technology or another technical field, as discussed in MPEP §§ 2106.04(d)(1) and 2106.05(a); (2) Applying or using a judicial exception to effect a particular treatment or prophylaxis for a disease or medical condition, as discussed in MPEP § 2106.04(d)(2); (3) Implementing a judicial exception with, or using a judicial exception in conjunction with, a particular machine or manufacture that is integral to the claim, as discussed in MPEP § 2106.05(b); (4) Effecting a transformation or reduction of a particular article to a different state or thing, as discussed in MPEP § 2106.05(c); and (5) Applying or using the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technological environment, such that the claim as a whole is more than a drafting effort designed to monopolize the exception, as discussed in MPEP § 2106.05(e). The additional elements recited in the instant claims are as follows: Additional elements of data gathering, including cells: Claims 1, 17, 25, and 30 recite additional elements of data gathering in the steps for obtaining a plurality of spectra of a plurality of cells. Claim 14 recites the cells are from the upper respiratory tract or are buccal cells. Claim 16 recites infrared spectroscopic, Fourier-transform infrared spectroscopic, benchtop spectroscopic, and/or Raman spectroscopic interrogations. Data gathering steps are additional elements which perform functions of inputting, collecting, and outputting the data needed to carry out the abstract idea. These steps are considered insignificant extra-solution activity, and are not sufficient to integrate an abstract idea into a practical application as they do not impose any meaningful limitation on the abstract idea or how it is performed, nor do they provide an improvement to technology [see MPEP 2106.04(d)(I)]. Additional elements of computer components: Claims 1, 3-4, 6-14, 16-18, 22, 24, and 25 recite the additional element of a non-transitory computer readable medium (CRM). The claims require only generic computer components, which do not improve computer technology, and do not integrate the recited judicial exception into a practical application (see MPEP 2106.04(d)(1) and MPEP 2106.05(f)). Step 2A Prong Two summary: The claims have been further analyzed with respect to Step 2A, Prong Two, and no additional elements have been found, alone or in combination, that would integrate the judicial exception into a practical application. (Step 2A, Prong Two: No). Step 2B: Because the additional claim elements do not integrate JE (in this case, the abstract ideas) into a practical application, the claims are further examined under Step 2B, which evaluates whether the additional elements, individually and in combination, amount to significantly more than the judicial exception itself by providing an inventive concept. An inventive concept is furnished by an element or combination of elements that is recited in the claim in addition to the judicial exception, and is sufficient to ensure that the claim, as a whole, amounts to significantly more than the judicial exception itself (see MPEP § 2106.05). The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the claims recite additional elements that are well-understood, routine, and conventional. Those additional elements are as follows: Additional elements of data gathering, including cells: The additional elements of: data gathering in claims 1, 17, 25, for obtaining a plurality of spectra of a plurality of cells; the upper respiratory tract cells or buccal cells of claim 14; and the infrared spectroscopic, Fourier-transform infrared spectroscopic, benchtop spectroscopic, and/or Raman spectroscopic interrogations of claim 16 do not cause the claims to rise to the level of significantly more than the judicial exception. The courts have recognized receiving or transmitting data over a network; and storing and retrieving information in memory; [see MPEP§2106.05(d)(II)], as well-understood, routine, conventional activity when they are claimed in a merely generic manner (e.g., at a high level of generality) or as extra-solution activity. Additionally, the following references show the additional elements of data gathering, for obtaining spectra from different cells, including sputum and/or buccal cells, to be well understood and conventional: Pahlow, (Applied spectroscopy, vol. 72(1_suppl), pp.52-84 (2018); cited on the attached form PTO-892), presents a review on vibrational spectroscopy and imaging to point-of-care medicine, and shows spectroscopy methods, including Fourier-transform infrared spectroscopic and Raman spectroscopy in lung cancer/tumors (p.55, col.1; p.69, col.1). Pahlow shows Raman spectroscopy in sputum analysis (p.57, col.1); and malignancy associated changes in the buccal mucosa probed by Raman spectroscopy in at risk patient groups from tobacco exposure (p.56, col.2). Pahlow shows investigations of single cells (p.62, cols.1-2; p.65, cols.1-2).; Talari, (Applied Spectroscopy Reviews, vol. 52(5), pp.456-506 (2017); cited on the attached form PTO-892), presents a review on advances in Fourier transform infrared (FTIR) spectroscopy of biological tissues. Talari shows FTIR microscopy of lung cancer cells and tissues (p.478 (para.3) through p. 480 (para.2)). Talari discloses FTIR spectra collected from lung cancer patients and healthy controls, showing Spectral bands in the region of 1800 to 950 cm-1 (p.480, para.2). Therefore the additional elements of data gathering are shown to be routine, well-understood, and conventional in the art, and do not provide an inventive concept needed to amount to significantly more than the judicial exception. Additional elements of computer components: The additional element of a CRM recited in claims 1, 3-4, 6-14, 16-18, 22, 24, and 25 does not cause the claims to rise to the level of significantly more than the judicial exception; this is a conventional computer component, which does not provide an inventive concept. Step 2B Summary: All limitations of claims 1, 3-4, 6-14, 16-18, 22, 24, 25, and 30 have been analyzed with respect to Step 2B, and none provides a specific inventive concept, as they all fail to rise to the level of significantly more than the identified judicial exception, and thus do not transform the judicial exception into a patent eligible application of the exceptions. (Step2B: NO). Therefore, the claims, when the limitations are considered individually and as a whole, are rejected under 35 U.S.C. § 101 as being directed to non patent-eligible subject matter. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Meredith A Vassell whose telephone number is (571)272-1771. The examiner can normally be reached 8:30 - 4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, KARLHEINZ SKOWRONEK can be reached at (571)272-9047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /M.A.V./Examiner, Art Unit 1687 /G. STEVEN VANNI/Primary patents examiner, Art Unit 1686
Read full office action

Prosecution Timeline

May 16, 2022
Application Filed
Jan 14, 2026
Non-Final Rejection mailed — §101, §112
Jul 14, 2026
Response Filed
Oct 20, 2026
Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781281
METHODS FOR IDENTIFYING AND MODULATING IMMUNE PHENOTYPES
8y 2m to grant Granted Nov 03, 2026
Patent 12718912
AUTOMATIC SAMPLE AND STANDARD PREPARATION BASED ON RECOGNITION OF SAMPLE IDENTITY AND SAMPLE TYPE
6y 11m to grant Granted Aug 25, 2026
Patent 12716845
METHODS OF DISEASE DETECTION AND CHARACTERIZATION USING COMPUTATIONAL ANALYSIS OF URINE RAMAN SPECTRA
5y 7m to grant Granted Aug 25, 2026
Patent 12699906
IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA
6y 9m to grant Granted Aug 04, 2026
Patent 12668837
METHOD FOR ANALYSING LOSS-OF-HETEROZYGOSITY (LOH) FOLLOWING DETERMINISTIC RESTRICTION-SITE WHOLE GENOME AMPLIFICATION (DRS-WGA).
4y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
30%
Grant Probability
76%
With Interview (+45.8%)
4y 8m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 67 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month